Outspoken Oncology

Stacie Dusetzina, PhD, department of health policy, Vanderbilt University School of Medicine, discusses the "desensitization" of society to cancer prescription drug costs, the role of advancing science in research and development and drug approvals for rare diseases, the H.R.3 bill in front of Congress, and solutions proposed by politicians for inflated Medicare Part D spending, among other topics. To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology. Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.

Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence in moving the needle for oncology care.

Gilberto Lopes, MD, editor-in-chief of the Journal of Global Oncology and creator of a global oncology program at the University of Miami Sylvester Comprehensive Cancer Center, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other topics.

Sumanta (Monty) Kumar Pal, MD, MD, GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more.

Gary Lyman, MD, MPH, senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice, as well as delves into issues of granting extrapolation.

Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care.

David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of "Chasing My Cure," discusses treating his own disease through experimental self-administered therapies, involvement in developing the first NCCN guidelines and FDA-approved drugs for Castleman disease, and how to effectively and systematically use off-label drugs for orphan diseases.

Matt Kalaycio, MD, Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics. To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology. Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.

Carla Tardif, CEO of Family Reach, sits down with Chadi to discuss the personal expenses that patients with cancer and their families are burdened with aside from medical care as well as the ways in which Family Reach is offering financial support for these families.

Anita Gruninger, RN and certified case manager, provides the often-forgotten perspective of a caregiver, including the emotional and financial toll a cancer diagnosis has on patients and their caregivers as well as the struggles of navigating the health care system.

Toni Choueiri, MD, kidney cancer specialist at Dana-Farber Cancer Institute, discusses surgical considerations and multidisciplinary care for localized kidney cancer, adjuvant therapies largely falling short of expectations, and the plethora of frontline therapies available in metastatic disease.

Aaron Gerds, MD, department of hematology and medical oncology, Cleveland Clinic, describes the benefits and pitfalls of Twitter as a platform for doctors to share their ideas and engage in the "ultimate peer-review process."

Ishwaria Subbiah, MD, MS, explains the value of having a dedicated team for oncology patient symptom management and demonstrates how using “supportive care” rather than “palliative care” can impact referrals.

At the Oncology Clinical Pathways Congress, Chadi sat down with Robin T Zon, MD, FACP, FASCO; Lee Schwartzberg, MD, FACP; and Tom Valuck, MD, JD, MHSA, to discuss pathway integration in value-based care models, OCM and other APMs, and the increasing role of employers in value-based care and payment.

Chadi picks the brain of Sayed Tabatabai, MD, a full-time nephrologist and avid writer that attempts to humanize and beautify the patient experience through a variety of written anecdotes in Twitter threads and short stories.